TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Transcranial Direct Current Stimulation (tDCS) to Study Implicit Motor Learning on Patients With Brain Injury
Brief Summary: The purpose of this study is to study motor learning and recovery of patients with brain damage caused by traumatic brain injury or stroke with transcranial direct current stimulation (tDCS). It is hypothesized that anodal tDCS on the lesion side and/or cathodal tDCS on the healthy side of motor cortex could improve the recovery of motor function such as learning.


Options:
A: Arm Label: non-invasive brain stimulation; Type: EXPERIMENTAL; Interventions: Device: Transcranial Direct Current Stimulation | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation; Assigned to Arm(s): non-invasive brain stimulation
B: Arm Label: Device-assisted therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Device-assisted therapy | Arm Label: Therapy-based occupational therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Therapy-based occupational therapy | Intervention Type: BEHAVIORAL; Name: Device-assisted therapy; Assigned to Arm(s): Device-assisted therapy | Intervention Type: BEHAVIORAL; Name: Therapy-based occupational therapy; Assigned to Arm(s): Therapy-based occupational therapy
C: Arm Label: Action Training; Type: ACTIVE_COMPARATOR; Interventions: Other: Action Training | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation | Arm Label: Action Training + tDCs; Type: EXPERIMENTAL; Interventions: Other: Transcranial direct current stimulation, Other: Action Training | Arm Label: Control training; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: OTHER; Name: Transcranial direct current stimulation; Assigned to Arm(s): Action Training + tDCs, tDCS | Intervention Type: OTHER; Name: Action Training; Assigned to Arm(s): Action Training, Action Training + tDCs
D: Arm Label: Dual-task training group; Type: EXPERIMENTAL; Interventions: Behavioral: Dual-task training group | Arm Label: Single-task training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Single-task training group | Arm Label: Flexibility and strength training group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Flexibility and strength training group | Intervention Type: BEHAVIORAL; Name: Dual-task training group; Assigned to Arm(s): Dual-task training group | Intervention Type: BEHAVIORAL; Name: Single-task training group; Assigned to Arm(s): Single-task training group | Intervention Type: BEHAVIORAL; Name: Flexibility and strength training group; Assigned to Arm(s): Flexibility and strength training group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Use of Transcranial Direct Current Stimulation (tDCS) to Study Implicit Motor Learning on Patients With Brain Injury
Brief Summary: The purpose of this study is to study motor learning and recovery of patients with brain damage caused by traumatic brain injury or stroke with transcranial direct current stimulation (tDCS). It is hypothesized that anodal tDCS on the lesion side and/or cathodal tDCS on the healthy side of motor cortex could improve the recovery of motor function such as learning.


Options:
A: Arm Label: non-invasive brain stimulation; Type: EXPERIMENTAL; Interventions: Device: Transcranial Direct Current Stimulation | Intervention Type: DEVICE; Name: Transcranial Direct Current Stimulation; Assigned to Arm(s): non-invasive brain stimulation
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy | Intervention Type: DEVICE; Name: Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy; Assigned to Arm(s): 2
C: Arm Label: Sham; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Arm Label: tDCS; Type: EXPERIMENTAL; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham, tDCS
D: Arm Label: real tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS | Arm Label: Sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham tDCS, real tDCS

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Proof of Concept, Phase 2a, Double-blind, Parallel Group, Randomised, Placebo-controlled Study to Assess the Effect of Lanthanum Carbonate on Intact FGF23 in Normo-phosphataemic Subjects With Stage 3 Chronic Kidney Disease
Brief Summary: To assess the effects of 12 weeks of treatment with lanthanum carbonate compared with placebo on serum intact Fibroblast Growth Factor 23 (FGF23) levels.


Options:
A: Arm Label: Lanthanum carbonate; Type: EXPERIMENTAL; Interventions: Drug: Lanthanum carbonate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Lanthanum carbonate; Assigned to Arm(s): Lanthanum carbonate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: PhosLo; Type: EXPERIMENTAL; Interventions: Drug: calcium acetate | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: calcium acetate; Assigned to Arm(s): PhosLo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: PA21; Type: EXPERIMENTAL; Interventions: Drug: PA21 (2.5 g tablet containing 500 mg iron) | Arm Label: Sevelamer carbonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer carbonate | Intervention Type: DRUG; Name: PA21 (2.5 g tablet containing 500 mg iron); Assigned to Arm(s): PA21 | Intervention Type: DRUG; Name: Sevelamer carbonate; Assigned to Arm(s): Sevelamer carbonate
D: Arm Label: ASP1585 dose #1; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #2; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: ASP1585 dose #3; Type: EXPERIMENTAL; Interventions: Drug: ASP1585 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Sevelamer hydrochloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevelamer hydrochloride | Intervention Type: DRUG; Name: ASP1585; Assigned to Arm(s): ASP1585 dose #1, ASP1585 dose #2, ASP1585 dose #3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Sevelamer hydrochloride; Assigned to Arm(s): Sevelamer hydrochloride

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Placebo-controlled, Three-way Crossover, Repeat Dose Pilot Study Comparing the Effect of Inhaled Fluticasone Furoate/GW642444M Combination and Fluticasone Furoate on the Allergen-induced Early Asthmatic Response in Subjects With Mild Asthma
Brief Summary: We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist (LABA)/ inhaled corticosteroid (ICS) combination product on protection from allergic triggers in asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: GW685698X; Type: EXPERIMENTAL; Interventions: Drug: GW685698X | Intervention Type: DRUG; Name: GW685698X; Assigned to Arm(s): GW685698X | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Fluticasone furoate/GW642444; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate/GW642444 | Arm Label: fluticasone furoate; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate | Intervention Type: DRUG; Name: Fluticasone Furoate/GW642444; Assigned to Arm(s): Fluticasone furoate/GW642444 | Intervention Type: DRUG; Name: Fluticasone furoate; Assigned to Arm(s): fluticasone furoate
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: inhaled corticosteroid(ICS)/long acting bronchodilator (LABA); Type: ACTIVE_COMPARATOR; Interventions: Drug: FF/Vilanterol (VI; GW642444M) | Arm Label: ICS; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone Furoate | Intervention Type: DRUG; Name: Fluticasone Furoate; Assigned to Arm(s): ICS | Intervention Type: DRUG; Name: FF/Vilanterol (VI; GW642444M); Assigned to Arm(s): inhaled corticosteroid(ICS)/long acting bronchodilator (LABA) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: GW642444M 25mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 50mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 100mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 200mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Arm Label: GW642444M 400mcg; Type: EXPERIMENTAL; Interventions: Drug: GW642444M for 14 days | Intervention Type: DRUG; Name: GW642444M for 14 days; Assigned to Arm(s): GW642444M 100mcg, GW642444M 200mcg, GW642444M 25mcg, GW642444M 400mcg, GW642444M 50mcg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Remote Ischemic Preconditioning on Exercise Capacity in Patients With Heart Failure: A Double Blind Randomized Control Trial
Brief Summary: The purpose of this study is to determine the effect of remote ischemic preconditioning on exercise capacity in patients with heart failure.


Options:
A: Arm Label: remote ischemic preconditioning; Type: EXPERIMENTAL; Interventions: Other: Remote ischemic preconditioning | Arm Label: Sham control; Type: SHAM_COMPARATOR; Interventions: Other: Sham Control | Intervention Type: OTHER; Name: Remote ischemic preconditioning; Assigned to Arm(s): remote ischemic preconditioning | Intervention Type: OTHER; Name: Sham Control; Assigned to Arm(s): Sham control
B: Arm Label: RIPC; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RIPC, Drug: isoflurane+sufentanil anesthesia | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Control, Drug: isoflurane+sufentanil anesthesia | Intervention Type: PROCEDURE; Name: RIPC; Assigned to Arm(s): RIPC | Intervention Type: PROCEDURE; Name: Control; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: isoflurane+sufentanil anesthesia; Assigned to Arm(s): Control, RIPC
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Remote ischemic preconditioning (RIPC) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: SHAM | Intervention Type: PROCEDURE; Name: Remote ischemic preconditioning (RIPC); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: SHAM; Assigned to Arm(s): 2
D: Arm Label: Sevoflurane; Type: EXPERIMENTAL; Interventions: Procedure: Sevoflurane preconditioning | Arm Label: No Sevoflurane; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Sevoflurane preconditioning; Assigned to Arm(s): Sevoflurane

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3, Placebo Controlled, Randomized, Double-blinded, Nonsteroidal Antiinflammatory Drug add-on, Clinical Trial of NPC-01 for Treatment of Dysmenorrhea
Brief Summary: The purpose of this study is to determine whether NPC-01 is effective in the treatment of dysmenorrhea.


Options:
A: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
B: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
C: Arm Label: NPC-01; Type: EXPERIMENTAL; Interventions: Drug: NPC-01 | Arm Label: IKH-01; Type: ACTIVE_COMPARATOR; Interventions: Drug: IKH-01 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: NPC-01; Assigned to Arm(s): NPC-01 | Intervention Type: DRUG; Name: IKH-01; Assigned to Arm(s): IKH-01 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Type: EXPERIMENTAL; Interventions: Drug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027), Drug: Placebo Match to SH T00658ID | Arm Label: Ethinyl estradiol, Levonorgestrel (Miranova); Type: ACTIVE_COMPARATOR; Interventions: Drug: Ethinyl estradiol, Levonorgestrel (Miranova), Drug: Placebo Match to SH D593B | Intervention Type: DRUG; Name: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027); Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Ethinyl estradiol, Levonorgestrel (Miranova); Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova) | Intervention Type: DRUG; Name: Placebo Match to SH T00658ID; Assigned to Arm(s): Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027) | Intervention Type: DRUG; Name: Placebo Match to SH D593B; Assigned to Arm(s): Ethinyl estradiol, Levonorgestrel (Miranova)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Response Study of Exercise for Age-related Cognitive Changes
Brief Summary: This is a randomized, 26-week study of supervised exercise assessing three doses of exercise in sedentary individuals 65 years of age and over with age-related cognitive changes. A total of 100 subjects (n=25 in each of four groups) will be randomized to a non-aerobic control group, 75 minutes, 150 minutes, or 225 minutes a week of moderate intensity aerobic exercise spread over 3 to 5 days a week for 26 weeks. These exercise doses represent 50%, 100%, or 150% of the recommended exercise dose. Participants will be directly supervised during all exercise sessions for the first two months after which direct supervision will occur during at least one session a week. This is intended to provide increased flexibility while also maintaining direct contact with the participant to enhance adherence. Aerobic fitness, physical function, and cognition will be assessed at baseline and 26 weeks to examine the dose-response relationships.


Options:
A: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise group
B: Arm Label: Nonexercise control group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Nonexercise control group | Arm Label: Aerobic Exercise Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Group 1 | Arm Label: Aerobic Exercise Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Group 2 | Arm Label: Aerobic Exercise Group 3; Type: EXPERIMENTAL; Interventions: Behavioral: Aerobic Exercise Group 3 | Intervention Type: BEHAVIORAL; Name: Nonexercise control group; Assigned to Arm(s): Nonexercise control group | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Group 1; Assigned to Arm(s): Aerobic Exercise Group 1 | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Group 2; Assigned to Arm(s): Aerobic Exercise Group 2 | Intervention Type: BEHAVIORAL; Name: Aerobic Exercise Group 3; Assigned to Arm(s): Aerobic Exercise Group 3
C: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A
D: Arm Label: Exercise Group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Control Group; Type: OTHER; Interventions: Other: Drug treatment | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise Group | Intervention Type: OTHER; Name: Drug treatment; Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Network Support for Alcohol Treatment: Mechanisms and Effectiveness
Brief Summary: The Network Support project is part of an ongoing effort to improve treatment for alcohol dependent patients. The Network Support Project is designed to help patients change their social network from one that reinforces drinking behavior to one that reinforces sobriety.

160 patients will be assigned to one of two treatments. Each of the treatments will last 12 weeks. The first is a Network Support (NS) treatment designed to help patients develop new acquaintances and social networks. It is expected that alcohol dependent patients will benefit from increasing their contact with non-drinking people. This NS condition will be compared to a packaged CBT program for alcoholics (PCBT) that is designed to teach a number of skills to help people stop drinking, but does not address social networks per se.

In order to better understand what is happening to the investigators patients, the investigators will be using daily computerized telephone calls to ask about people's experiences. This will be done both before and after treatment. Patients will also be asked to participate in follow-up interviews every 3 months for 2 years following the end of treatment.


Options:
A: Arm Label: MBRP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mindfulness Based Relapse Prevention | Arm Label: Relapse Prevention (RP); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Relapse Prevention | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Relapse Prevention; Assigned to Arm(s): MBRP | Intervention Type: BEHAVIORAL; Name: Relapse Prevention; Assigned to Arm(s): Relapse Prevention (RP) | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
B: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A
C: Arm Label: Network Support; Type: EXPERIMENTAL; Interventions: Behavioral: Coping Skills Training | Arm Label: Packaged Cognitive-Behavioral Treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Coping Skills Training | Intervention Type: BEHAVIORAL; Name: Coping Skills Training; Assigned to Arm(s): Network Support, Packaged Cognitive-Behavioral Treatment
D: Arm Label: Introduction to AA volunteer; Type: OTHER; Interventions: Other: Introduction to AA volunteer | Arm Label: AA materials offered; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Introduction to AA volunteer; Assigned to Arm(s): Introduction to AA volunteer

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Classification Based 'Cognitive Functional Therapy' in Patients With Non Specific Chronic Low Back Pain (NSCLBP) - A Randomized Controlled Trial
Brief Summary: A randomized controlled trial of the efficacy of classification based cognitive functional physiotherapy according to the system proposed by Peter O'Sullivan as compared to manual therapy and exercise in patients with non specific chronic low back pain.

The investigators hypothesis was that treatment targeted at the mechanism behind the problem from a multidimensional perspective would be superior to traditional treatment.


Options:
A: Arm Label: Cognitive Functional Therapy; Type: EXPERIMENTAL; Interventions: Other: Cognitive Functional Therapy | Arm Label: Manual Therapy and Exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual therapy and exercise | Intervention Type: OTHER; Name: Cognitive Functional Therapy; Assigned to Arm(s): Cognitive Functional Therapy | Intervention Type: OTHER; Name: Manual therapy and exercise; Assigned to Arm(s): Manual Therapy and Exercise
B: Intervention Type: BEHAVIORAL; Name: Fear-reducing Information; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Symptom-based exercise; Assigned to Arm(s): N/A
C: Arm Label: Education group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education on active management, Other: Group GDS physiotherapy, Other: Individual GDS physiotherapy | Arm Label: Group GDS physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Group GDS physiotherapy, Other: Individual GDS physiotherapy | Arm Label: Individual GDS physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Individual GDS physiotherapy | Intervention Type: BEHAVIORAL; Name: Education on active management; Assigned to Arm(s): Education group | Intervention Type: OTHER; Name: Group GDS physiotherapy; Assigned to Arm(s): Education group, Group GDS physiotherapy | Intervention Type: OTHER; Name: Individual GDS physiotherapy; Assigned to Arm(s): Education group, Group GDS physiotherapy, Individual GDS physiotherapy
D: Arm Label: Sensorimotor; Type: EXPERIMENTAL; Interventions: Other: Proprioceptive postural training, Other: Conventional physiotherapy | Arm Label: Low-intensity activity; Type: ACTIVE_COMPARATOR; Interventions: Other: Treadmill training, Other: Conventional physiotherapy | Intervention Type: OTHER; Name: Proprioceptive postural training; Assigned to Arm(s): Sensorimotor | Intervention Type: OTHER; Name: Treadmill training; Assigned to Arm(s): Low-intensity activity | Intervention Type: OTHER; Name: Conventional physiotherapy; Assigned to Arm(s): Low-intensity activity, Sensorimotor

Answer: A